FindTrial
Sign In

Pemetrexed 500 mg/m2

DRUG6 trials

Sponsors

Eli Lilly and Company, Sun Yat-sen University, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Inhibrx Biosciences, Inc, Shanghai Chest Hospital

Conditions

Gastric CancerHead and Neck CancerLocally Advanced Non-Small Cell Lung CancerLung CancerMelanomaNSCLCNon-Small Cell Lung CancerNon-small Cell Lung Cancer

Phase 1

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Active, not recruitingNCT04198766
Inhibrx Biosciences, IncGastric Cancer, Head and Neck Cancer, Melanoma +4
Start: 2019-12-10End: 2027-05-12Updated: 2025-12-18

Phase 2

To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)
CompletedNCT00191191
Eli Lilly and CompanyNon-small Cell Lung Cancer
Start: 2004-10-31End: 2008-10-31Updated: 2009-12-09
S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC
NCT02631460
Sun Yat-sen UniversityNSCLC
Start: 2015-12-31End: 2019-12-31Target: 470Updated: 2015-12-16
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
CompletedNCT04177953
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestPleural Mesothelioma Malignant
Start: 2019-02-04End: 2025-01-30Updated: 2025-02-06
Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC
Not yet recruitingNCT06688656
Shanghai Chest HospitalLung Cancer
Start: 2025-03-31End: 2028-03-31Target: 30Updated: 2024-11-14
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
Not yet recruitingNCT07309952
Yang HongLocally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
Start: 2025-12-31End: 2032-10-31Target: 28Updated: 2025-12-30

Related Papers

INBRX-106, a novel Hexavalent OX40 agonist, potentiates T-cell receptor clustering, leading to improved activation and potent anti-tumor responses 3058
The Journal of Immunology2025-11-01
HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥20.
Journal of Clinical Oncology2025-05-28
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering
Journal for ImmunoTherapy of Cancer2025-05-014 citations
748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
Regular and Young Investigator Award Abstracts2023-10-311 citations
1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice
Regular and Young Investigator Award Abstracts2023-10-31
Nivolumab with chemotherapy in pleural mesothelioma after surgery: The NICITA trial.
Journal of Clinical Oncology2023-06-011 citations
856 INBRX-106: a novel hexavalent anti-OX40 agonist for the treatment of solid tumors
Regular and Young Investigator Award Abstracts2021-11-019 citations
A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
2020-10-1412 citations